This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Mavenclad
  • /
  • A Safety and Efficacy Study of Oral Cladribine in ...
Clinical trial

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CLARITY)

Read time: 2 mins
Last updated:1st Apr 2005
Identifier: NCT00213135

The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Enrollment: 1326
Study Start Date: April 2005
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Cladribine 5.25 mg/kg
- Experimental: Cladribine 3.5 mg/kg
- Placebo Comparator: Placebo


Related journal:
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.

Category Value
Date last updated at source 2014-01-10
Study type(s) Interventional
Expected enrolment 1326
Study start date 2005-04-01
Estimated primary completion date 2008-11-01

View full details